期刊文献+

蒽环类药物的心脏毒性及其保护剂的研究进展 被引量:2

原文传递
导出
摘要 蒽环类药物是一类临床疗效肯定、目前广泛应用于恶性肿瘤治疗的化疗药物,但其剂量累积性心脏毒性的严重副作用限制了其临床应用.化疗中如能早期发现患者的心脏毒性并积极防治,将有助于治疗的顺利完成及提高化疗后的生存率.目前监控手段主要有心电图、超声心动图、放射性核素心肌显像以及生化指标的测定等.防治方法主要包括化疗前评估危险因素,化疗期间控制药物累积剂量、选用高效低毒的蒽环类药物,以及使用心脏保护剂.目前心脏保护剂的研究重点主要是抗氧化剂和铁螯合剂,其中右丙亚胺是典型代表.
出处 《国际输血及血液学杂志》 CAS 2010年第5期430-434,共5页 International Journal of Blood Transfusion and Hematology
  • 相关文献

参考文献28

  • 1Floyd JD,Nguyen DT,Lobins RL.Cardiotoxicity of cancer therapy.J Clin Oncol,2005,23(30):7685-7696.
  • 2Otero FJ,Boor PJ,Sheahan RG..Cardiology Grand Rounds from The University of Texas Medical Branch:DoxorubicinInduced Cardio-myopathy.Am J Med Sci,2000,320(1):59-63.
  • 3Kim SY,Kim SJ,Kim BJ,et al.Doxorubicin-induced reactive oxygen species generation and intracellular Ca2 + increase are reciprocally modulated in rat cardiomyocytes.Exp Mol Med,2006,38(5):535-545.
  • 4Nelson MA,Frishman WH,Seiter K,et al.Cardiovascular considerations with anthracycline use in patients with cancer.Heart Dis,2001,3(3):157-168.
  • 5Schwarta RG,McKenzie WB,Alexander J,et al.Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy.Am J Med,1987,82(6):1109-1118.
  • 6Hequet O,Le QH,Moullet I,et al.Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults.J Clin Oncol,2004,22(10):1864-1871.
  • 7Yeh ET,Tong AT,Lenihan DJ,et al.Cardiovascular complications of cancer therapy:diagnosis,pathogenesis,and management.Circulation,2004,109(25):3122-3131.
  • 8Goethals I,De Winter O,De Bondt P,et al.The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline -associated cardiac damage.Ann Oncol,2002,13(9):1331-1339.
  • 9Birtle AJ.Anthracyclines and cardiotoxicity.Clin Oncol,2000,12(3):146-152.
  • 10Jones RL,Miles DW.Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity.Lancet Oncol,2005,6(2):67.

二级参考文献13

共引文献39

同被引文献17

  • 1Lipshultz SE, Rifai N, Sallan SE, et al. Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury [ J ]. Circulation, 1997,96 (8) :2641 - 2648.
  • 2Van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective in- terventions for cancer patients receiving anthracyclines [ J ]. Co- chrane Database Syst Rev,2011,15(6) :3917.
  • 3Rathe M, Carlsen NL, Oxhoj H. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia [ J ]. Pediar blood cancer,2007,48 (7) :663 - 667.
  • 4Ganame J, Claus P, Uyttebroeck A, et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric pa- tients[ J]. J Am Soc Echocardiogr,2007,20(12) :1351 - 1358.
  • 5Junjing Z, Yan Z, Baolu Z. Scavenging effects of dexrazoxane on free radicals [ J ]. J Clin Biochem Nutr,2010,47 ( 3 ) :238 - 245.
  • 6Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity [ J ]. Ann Pharmacother,2008,42 ( 1 ) :99 - 104,.
  • 7陈新谦;金有豫;汤光.新编药物学[M]北京:人民卫生出版社,2010742.
  • 8中国临床肿瘤学会;中华血液学会;哈尔滨血液病肿瘤研究所.防治蒽环类抗肿瘤药物心脏毒性的中国专家共识(2011版)[J]中华肿瘤杂志,2011(12):1122-1129.
  • 9Junjing Z,Yan Z,Baolu Z. Scavenging-effects of dexrazoxane on free radicals[J].Journal of Clinical Biochemistry and Nutrition,2010,(03):238-245.
  • 10吕俊,丁念,朱家蔷,高霞.蒽环类药物心脏毒性及其预防的研究进展[J].中国医院药学杂志,2008,28(15):1302-1303. 被引量:19

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部